Enveric Biosciences Ownership
ENVB Stock | USD 0.34 0.01 2.86% |
Shares in Circulation | First Issued 1993-09-30 | Previous Quarter 7.6 M | Current Value 8.7 M | Avarage Shares Outstanding 389.3 K | Quarterly Volatility 1.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Enveric |
Enveric Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.88. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enveric Biosciences recorded a loss per share of 2.42. The entity last dividend was issued on the 23rd of April 2008. The firm had 1:50 split on the 15th of July 2022. Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Enveric Biosciences, Inc. is headquartered in Naples, Florida. Enveric Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 23 people. To learn more about Enveric Biosciences call Joseph Tucker at 239-302-1707 or check out https://www.enveric.com.Besides selling stocks to institutional investors, Enveric Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Enveric Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Enveric Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Enveric Biosciences Quarterly Liabilities And Stockholders Equity |
|
About 7.0% of Enveric Biosciences are currently held by insiders. Unlike Enveric Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Enveric Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Enveric Biosciences' insider trades
Enveric Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enveric Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enveric Biosciences backward and forwards among themselves. Enveric Biosciences' institutional investor refers to the entity that pools money to purchase Enveric Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Bank Of America Corp | 2024-06-30 | 164 | Nelson, Van Denburg & Campbell Wealth Management Group, Llc | 2024-09-30 | 50.0 | Wells Fargo & Co | 2024-06-30 | 16.0 | Mather Group, Inc. | 2024-06-30 | 8.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Fmr Inc | 2024-09-30 | 0.0 | Org Partners Llc | 2024-09-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Advisorshares Investments, Llc | 2024-06-30 | 317 K | Geode Capital Management, Llc | 2024-06-30 | 44.7 K |
Enveric Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enveric Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enveric Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enveric Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dickey Robert Iv over a month ago Insider Trading | ||
Coveney Kevin Michael over a month ago Acquisition by Coveney Kevin Michael of 100000 shares of Enveric Biosciences subject to Rule 16b-3 | ||
Sikaria Lokesh over a month ago Disposition of 14119 shares by Sikaria Lokesh of Enveric Biosciences at 0.3003 subject to Rule 16b-3 | ||
Lokesh Sikaria Trust Dated 12/14/2012 over two months ago Disposition of 14119 shares by Lokesh Sikaria Trust Dated 12142012 of Enveric Biosciences at 0.3003 subject to Rule 16b-3 | ||
Sikaria Lokesh over three months ago Disposition of 1500 shares by Sikaria Lokesh of Enveric Biosciences at 0.3011 subject to Rule 16b-3 | ||
Dewitt Sheila over three months ago Insider Trading | ||
Sikaria Lokesh over six months ago Disposition of 1515 shares by Sikaria Lokesh of Enveric Biosciences at 0.3006 subject to Rule 16b-3 | ||
Joseph Tucker over a year ago Acquisition by Joseph Tucker of 44000 shares of Enveric Biosciences subject to Rule 16b-3 |
Enveric Biosciences Outstanding Bonds
Enveric Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enveric Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enveric bonds can be classified according to their maturity, which is the date when Enveric Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 37.678 | Quarterly Revenue Growth (0.07) | Return On Assets (0.81) | Return On Equity (2.06) |
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.